Frontlight ResearchEarly access
Taking peoplePhase 1
NG004 antibody for adults with recent incomplete spinal cord injury in the neck
Tests the antibody NG004 against placebo in adults with recent incomplete neck spinal cord injury.
Key facts
- Who runs it
- NovaGo Therapeutics AG
- Where
- Germany8 sites in 1 countryChoose a country to see its sites
- Trial code
- EU 2026-526089-26-00
- U1111-1337-0474
- Registry title
- A randomized, double-blind, placebo-controlled clinical trial to investigate the human monoclonal antibody NG004 in acute, incomplete cervical spinal cord injury (SCI) patients
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 84 people, planned
- Started
- 21 Sept 2026
- Expected to end
- 30 Jun 2029
- Type of study
- Interventional
- Record updated
- 14 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a recent (acute), incomplete injury of the spinal cord in the neck. It tests the antibody NG004 against a placebo (dummy treatment).
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Acute, incomplete cervical (neck) spinal cord injury
Main reasons for not taking part
- Healthy volunteers cannot join
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- NG004 antibody for adults with recent incomplete spinal cord injury in the neckGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 14 October 2026